Positive Amicus Preliminary Results From Chaperone-ERT; Arrowhead Announces New Study in Anti-Obesity Drug Print E-mail
By Staff and Wire Reports   
Tuesday, 26 June 2012 18:53

Below is a look at some of the headlines for companies that made news in the healthcare sector on June 26, 2012.

Amicus Therapeutics (Nasdaq: FOLD), announced positive preliminary results from an ongoing Phase 2 open-label drug-drug interaction study (Study 010) to evaluate the safety and pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease.

 


John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics said, "Positive preliminary results from the first two lower dose cohorts in Study 010 further validate our chaperone-ERT combination platform technology. This study represents the second time in which we have seen consistent enhancement of ERT activity with different chaperones co-administered with different ERTs in clinical studies for two different lysosomal storage disorders. It is a great step forward in the development of this Amicus platform technology in Pompe disease and we look forward to additional important data from the remaining two cohorts in this clinical study."

AT2220 is an investigational oral pharmacological chaperone being developed exclusively by Amicus. Study 010 is investigating four ascending doses of AT2220 co-administered with the ERT alglucosidase alfa (Myozyme®/Lumizyme®), the first and only treatments approved for Pompe disease. In addition to safety and plasma PK effects, enzyme uptake into muscle tissue is being measured with and without AT2220.


=====


Arrowhead Research Corporation (NASDAQ: ARWR)
, a targeted therapeutics company, announced the publication of data demonstrating that its anti-obesity drug candidate, Adipotide, induces rapid metabolic changes with implications for Type II diabetes. An independent laboratory reported that obese mice treated with Adipotide displayed significantly improved insulin sensitivity, improved glucose tolerance, and a reduction in serum triglycerides after only 2-3 days of treatment. These effects occurred independent of and prior to Adipotide-induced weight loss. The findings, published online ahead of print in the Journal of the American Diabetes Association (Diabetes Epub June 25, 2012), are presented in a paper titled "Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium." The research team is led by Director of the Cincinnati Diabetes and Obesity Center, Dr. Randy Seeley.

"A large amount of data generated over the past eight years across multiple laboratories have suggested that Adipotide is a unique and potentially powerful agent against the obesity epidemic,” said Dr. Christopher Anzalone, President and Chief Executive Officer of Arrowhead. “This new study suggests that it may also be a powerful agent against obesity's sister epidemic, Type II diabetes. The extent and speed of the effects reported by Dr. Seeley's group are truly striking. We have always been excited about this new suite of anti-obesity drug candidates for many reasons, including: the unique mode of action; rapid weight loss seen in rodents and non-human primates; and data suggesting that animals have decreased appetites while they are losing weight. The current study adds a new dimension to the program and expands the potential reach to include Type II diabetes. We are looking forward to the results of the first human study."


=====

 
Medifocus Inc. (Medifocus or the Company) (MFS.V)(MDFZF)
the tiny Ontario based company which trades on the venture and OTC exhanges announced an agreement with Boston Scientific Corporation (BSX) for the purchase of all of the assets of its Prolieve® business, which sells devices for the treatment of Benign Prostatic Hyperplasia (BPH). BPH is the enlargement of the male prostate gland which affects over 50% of men over the age of 50. Prolieve is a patent protected device utilizing a unique combination of microwave heating and dilation of the prostatic urethra to offer immediate relief of symptoms such as weak urinary stream and urgency caused by BPH.This news should take the company from strictly a research and development firm to a revenue producer. Developing...


Also Tuesday:

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes,today announced that the results of a recent interim analysis of data from an ongoing MuGard clinical trial will be presented at a joint international symposium of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) on Supportive Care in Cancer.

AeroGrow International, Inc. (OTCQB: AERO) (PINKSHEETS: AERO)
("AeroGrow" or the "Company"), makers of the AeroGarden® line of indoor gardening products, announced results for the fiscal year ended March 31, 2012.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that final Phase 3 results for its oral ghrelin agonist, AEZS-130, show that the drug is safe and effective in diagnosing adult growth hormone deficiency (AGHD).

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR)
today announced a plan to open its Asia Operations Center in Taipei, Taiwan.

American Bio Medica Corporation (ABMC.PK)
announces that the United States Patent & Trademark office has granted a patent to the Company for its all inclusive urine point of collection drug test cup product lines, the Rapid TOX Cup II and the RDS® InCup.

Antares Pharma, Inc. (NASDAQ: ATRS)
today announced positive results from a human factors usability study for VIBEX Methotrexate (MTX), a proprietary auto injector product designed to self-administer a rapid subcutaneous weekly injection of methotrexate for the treatment of rheumatoid arthritis (RA).

Arrowhead Research Corporation (NASDAQ: ARWR)
, a targeted therapeutics company, today announced the publication of data demonstrating that its anti-obesity drug candidate, Adipotide, induces rapid metabolic changes with implications for Type II diabetes.

Axia Group's (AGIJ) (PINKSHEETS:AGIJ)
, (http://www.axiagroup.com/) Collagenna Skin Care Products is pleased to announce that it will open 2 more corporate owned clinics in the third quarter 2012.

Baxter International Inc. (NYSE: BAX)
today announced its SIGMA Spectrum Infusion System has received the ''Best in KLAS'' award for the second consecutive time in the Smart Pumps – Large Volume Pump1 category of the 2012 Best in KLAS Awards: Medical Equipment & Infrastructure report.

Cellceutix Corporation (OTCBB: CTIX)
(the "Company"), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, is pleased to follow-up on its press release from Friday, June 22, 2012 in which the Company announced that the U.S. Food and Drug Administration ("FDA") has approved the Investigational New Drug (IND) application for Kevetrin™, Cellceutix's novel anti-cancer compound.

Cortex Pharmaceuticals, Inc. (OTCBB: CORX) announced that it has completed a private placement of a non-convertible secured promissory note in principal amount of approximately $0.4 million (₩465,000,000 South Korean won) with Samyang Optics Co., Ltd. (“Samyang”) of Korea.

Incyte Corporation (Nasdaq : INCY) announced today it will present at the JMP Securities 7th Annual Healthcare Conference on Thursday, July 12, 2012 at 12:00 p.m. (ET) in New York.

Ingram Micro Inc. (NYSE: IM)
today announced it will co-host the 2012 Health IT Innovation Summit on June 28 at the Nixon Presidential Library in Yorba Linda, Calif., in conjunction with HIMSS' Southern California chapter and UC Irvine's Center for Digital Transformation.

Intuitive Surgical, Inc. (NASDAQ : ISRG)
, the leader in operative surgical robotics, will hold its quarterly conference call to discuss Second Quarter 2012 results, Thursday, July 19, at 4:30 p.m. Eastern Time.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)
a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, has launched Hypoparathyroidism.com, an educational website for patients and caregivers dealing with this rare and complex disorder.

The National Association of People with AIDS (NAPWA) and OraSure Technologies, Inc. (NASDAQ: OSUR) announced an expected lineup of speakers who will address a range of issues related to HIV/AIDS at a Hill press conference that will be held 11 a.m. today, in observance of National HIV Testing Day on June 27.

OncoSec Medical Inc. (OTCBB:ONCS)
, a company developing the OncoSec Medical System (OMS) ElectroOncology therapies to treat advanced-stage solid tumors, announced that Dr. Adil Daud, principal investigator, presented preliminary enrollment and safety data at the Second European Post-Chicago Melanoma Meeting in Munich, Germany for the company's on-going Phase II metastatic melanoma clinical trial, OMS-I100.

POZEN Inc. (NASDAQ: POZN)
, a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the United States Patent and Trademark Office has issued to POZEN U.S. Patent 8,206,741 titled ‘Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs’.

PROLOR Biotech, Inc. (NYSE MKT: PBTH)
today reported that researchers at ENDO 2012 presented data from the company's Phase II trial of its long acting human growth hormone, hGH-CTP, in growth hormone deficient adults.

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT)
, a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

RXi Pharmaceuticals Corporation (OTCBB: RXII.OB)
today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology.

Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line.

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today announced the launch of Thoratec Connect™, the first Cloud-based advanced MCS program management system.

Recognizing that access to HIV testing, education and care are critical to the treatment and prevention of the complex condition, Walgreens (NYSE: WAG) (NASDAQ: WAG) today announced its participation in an innovative Centers for Disease Control and Prevention (CDC) pilot program to help connect more people with HIV to care.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter